




Full-Length Transmembrane Proteins



Active, full-length transmembrane proteins are popular drug discovery targets, but are difficult to produce in their native configuration. KACTUS offers various bioactive, full-length transmembrane proteins with native epitopes. We use Virus-Like Particles (VLPs) to display the proteins with original folding. The VLP is engineered to display the transmembrane protein epitope on the outer surface. They do not contain viral infectious genomes and offer high immunogenicity. Recombinant transmembrane proteins allow for differentiated antibody drug discovery.

VLPs are nanoparticles formed by the automatic assembly of viral capsid proteins. The VLP stabilizes the natural configuration of the transmembrane protein and allows for more accurate binding activity by facilitating the use of the full-length protein.



Fluorescent Human Claudin 18.2 VLP used to detect the positive population of anti-Claudin 18.2 CAR 293T cells.

Available Targets Presented on VLPs:

Claudin 18.2	Claudin 6
TM4SF1	GPCR5D
CD20	CD24
CCR2b	

Biotinylated and non-biotinylated versions available

KACTUS transmembrane proteins are bioactive and show increased immunogenicity when used for immunization. They are also ideal for antibody screening and CMC analysis (i.e. ELISA & SPR)

www.stratech.co.uk

+44 (0) 1638 782600

orders@stratech.co.uk

 @stratech_uk

 @stratechscientifictd

 @stratech-scientific-ltd